Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-aminopyridine for Chronic GBS
NCT00056810Phase 2Completed
- Sponsor
- Food and Drug Administration
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in Guillain-Barré syndrome (GBS) (2 arms), sponsored by Food and Drug Administration. Primary endpoints: American Spinal Injury Association Motor Score at 19 weeks and Functional Independence Measure Motor scale at 19 weeks. Started Sep 2002; status: completed.
02
Drugs
dalfampridine
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT00056810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056810.